Strategies Targeting the Hallmarks of Cancer - This figure illustrates some of the many approaches employed in developing therapeutics targeted to the known and emerging hallmarks of cancer. EGFR indicates epidermal growth factor receptor; CTLA4, cytotoxic T lymphocyte-associated antigen 4; mAb, monoclonal antibody; HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factor; PARP, poly-(ADP ribose) polymerase.
Nearly a quarter of advanced lung cancer patients fail to receive epidermal growth factor receptor (EGFR) gene mutation test results before starting treatment, according to a new survey of oncologists in 10 countries.
National Guideline Clearinghouse | Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline.
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline: Journal of Clinical Oncology: Vol 32, No 29